 |
More than 25,000 Devices Implanted Worldwide from 2010-20251
ALISO VIEJO, Calif., March 19, 2025 /PRNewswire/ -- Terumo Neuro, a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, proudly marks the 15th anniversary of the groundbreaking WEBâ„¢ Aneurysm Embolization System. Since its introduction, the WEB device has transformed the treatment of wide-neck bifurcation aneurysms, offering physicians and patients a clinically proven, single-device solution – One and Done – with proven simplicity, proven safety and durability, proven for ruptured aneurysms* and proven innovation2-9. The WEB device was commercially launched in October 2010 after receiving its CE (Conformité Européenne) Mark in Europe. The first implant was performed by Prof. Joachim Klisch in Germany, paving the way for a new era in aneurysm treatment.
The WEB device has proven clinical data, supported by seven global Good Clinical Practice (GCP) studies2-8 and over 200 peer-reviewed publications. Over the past 15 years, this revolutionary technology has changed the paradigm for aneurysm treatment, providing a safe, effective alternative to traditional methods.
Carsten Schroeder, President and CEO of Terumo Neuro, commented on this significant milestone: "The WEB device has set a new standard in aneurysm treatment and has been instrumental in our mission to drive game-changing impact in neurovascular care. With 15 years of proven clinical success, WEB continues to advance patient outcomes, reducing the need for multiple devices and lengthy procedures. As we celebrate this achievement, we remain committed to innovating alongside leading physicians worldwide to shape the future of neurovascular care."
Transforming Aneurysm Treatment with the WEB Device
The WEB device is the world's first intrasaccular flow disruptor, designed to treat brain aneurysms from inside the aneurysm sac. Unlike traditional treatments for wide-neck bifurcation aneurysms that require stents and coils, this device minimizes the need for dual antiplatelet therapy, simplifying procedures and enhancing patient safety, with a single device. Key milestones and clinical highlights of Terumo Neuro's WEB embolization system include:
- Unparalleled Clinical Data: The WEB device has been studied in over 600 patients across seven GCP trials, accumulating more than 1,464 patient-years with zero recorded rebleeds in a WEB device-treated aneurysm.2-8
- Proven Long-Term Safety & Durability: The five-year follow-up data from the WEB-IT, WEBCAST and WEBCAST 2 trials reaffirmed the WEB system's sustained efficacy and safety, including 0% device-related morbidity and mortality.7,8
- Expanding Treatment Options: The introduction of the WEB 17 system, a lower profile system to treat smaller aneurysms, has further refined aneurysm treatment providing physicians with greater flexibility and precision for a wider range of cases.
The WEB device's continued evolution underscores Terumo Neuro's dedication to advancing neurovascular technology. With more than 25,000 patients treated with the WEB device worldwide, this intrasaccular device remains the trusted choice for physicians seeking a reliable, single-device solution for wide-neck bifurcation aneurysms.
About Terumo Neuro (Formerly MicroVention, Inc.)
We are in business to create and deliver Game-changing Impact™—innovations that redefine what is possible in neuroendovascular treatment to meaningfully advance both physician practice and patient outcomes. Founded in 1997 as MicroVention and acquired by Terumo Corporation in 2006, Terumo Neuro offers more than thirty products for the treatment of cerebral aneurysms, ischemic stroke, carotid artery disease, and neurovascular malformations. Headquartered in California, Terumo Neuro products are sold in more than seventy countries through a direct sales organization as well as strategic distribution partnerships. Manufacturing facilities are in Aliso Viejo, California, and San José, Costa Rica. For more information on Terumo Neuro, please visit www.terumoneuro.com.
About Terumo Corporation
Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for one hundred years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice. Terumo will further strive to be of value to patients, medical professionals, and society at large. For full indications for use, visit: WEBâ„¢ Embolization System | Terumo Neuro
*Information provided may not represent the approved indication for use for each country/market. Please refer to the Instruction for Use (IFU) in the specific market/country that you are looking into.
References:
- Data on file, Terumo Neuro.
- Pierot L, Moret J, Barreau X, et al. Safety and efficacy of aneurysm treatment with WEB in the cumulative population of three prospective, multicenter series. J Neurointerv Surg. 2018;10(6):553-559.
- Arthur AS, Molyneux A, Coon AL, et al. The safety and effectiveness of the Woven EndoBridge (WEB) system for the treatment of wide-necked bifurcation aneurysms: final 12-month results of the pivotal WEB Intrasaccular Therapy (WEB-IT) Study. J Neurointerv Surg. 2019;11(9):924-930.
- Pierot L, Moret J, Turjman F, Herbreteau D, et al. WEB Treatment of Intracranial Aneurysms: Clinical and Anatomic Results in the French Observatory. AJNR. 2016.
- Spelle, L., et al. (2022) "Clinical Assessment of WEB device in Ruptured Aneurysms (CLARYS): 12-month angiographic results of a multicenter study." J NeuroIntervent Surg.
- Spelle, L., et al. (2024) "Clinical Evaluation of WEB 17 device in intracranial aneurysms (CLEVER): 1-year effectiveness results for ruptured and unruptured aneurysms." J NeuroIntervent Surg.
- Pierot L, Szikora I, Barreau X, et al. Aneurysm treatment with the Woven EndoBridge (WEB) device in the combined population of two prospective, multicenter series: 5-year follow-up. J Neurointerv Surg. 2023;15(6):552-557.
- Fiorella D, Molyneux A, Coon A, et al. Safety and effectiveness of the Woven EndoBridge (WEB) system for the treatment of wide necked bifurcation aneurysms: final 5 year results of the pivotal WEB Intra-saccular. Therapy study (WEB-IT). J Neurointerv Surg. 2023;15(12):1175-1180.
- Rai AT, Turner RC, Brotman RG, Boo S. Comparison of operating room variables, radiation exposure and implant costs for WEB versus stent assisted coiling for treatment of wide neck bifurcation aneurysms. Interv Neuroradiol. 2021;27(4):465-472.
WEBâ„¢ is a trademark of MicroVention, Inc., registered in the United States and other jurisdictions. All brand names are trademarks or registered trademarks owned by TERUMO CORPORATION, its affiliates, or unrelated third parties. ©2024 MicroVention, Inc. MM2034(i) WW 03/25
Media Contact:
Christine McCullough
Global Corporate Communications
Terumo Neuro
+ 1 714 206 9800
christine.mccullough@microvention.com
More than 25,000 Devices Implanted Worldwide from 2010-20251
ALISO VIEJO, Calif., March 19, 2025 /PRNewswire/ -- Terumo Neuro, a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, proudly marks the 15th anniversary of the groundbreaking WEBâ„¢ Aneurysm Embolization System. Since its introduction, the WEB device has transformed the treatment of wide-neck bifurcation aneurysms, offering physicians and patients a clinically proven, single-device solution – One and Done – with proven simplicity, proven safety and durability, proven for ruptured aneurysms* and proven innovation2-9. The WEB device was commercially launched in October 2010 after receiving its CE (Conformité Européenne) Mark in Europe. The first implant was performed by Prof. Joachim Klisch in Germany, paving the way for a new era in aneurysm treatment.
The WEB device has proven clinical data, supported by seven global Good Clinical Practice (GCP) studies2-8 and over 200 peer-reviewed publications. Over the past 15 years, this revolutionary technology has changed the paradigm for aneurysm treatment, providing a safe, effective alternative to traditional methods.
Carsten Schroeder, President and CEO of Terumo Neuro, commented on this significant milestone: "The WEB device has set a new standard in aneurysm treatment and has been instrumental in our mission to drive game-changing impact in neurovascular care. With 15 years of proven clinical success, WEB continues to advance patient outcomes, reducing the need for multiple devices and lengthy procedures. As we celebrate this achievement, we remain committed to innovating alongside leading physicians worldwide to shape the future of neurovascular care."
Transforming Aneurysm Treatment with the WEB Device
The WEB device is the world's first intrasaccular flow disruptor, designed to treat brain aneurysms from inside the aneurysm sac. Unlike traditional treatments for wide-neck bifurcation aneurysms that require stents and coils, this device minimizes the need for dual antiplatelet therapy, simplifying procedures and enhancing patient safety, with a single device. Key milestones and clinical highlights of Terumo Neuro's WEB embolization system include:
- Unparalleled Clinical Data: The WEB device has been studied in over 600 patients across seven GCP trials, accumulating more than 1,464 patient-years with zero recorded rebleeds in a WEB device-treated aneurysm.2-8
- Proven Long-Term Safety & Durability: The five-year follow-up data from the WEB-IT, WEBCAST and WEBCAST 2 trials reaffirmed the WEB system's sustained efficacy and safety, including 0% device-related morbidity and mortality.7,8
- Expanding Treatment Options: The introduction of the WEB 17 system, a lower profile system to treat smaller aneurysms, has further refined aneurysm treatment providing physicians with greater flexibility and precision for a wider range of cases.
The WEB device's continued evolution underscores Terumo Neuro's dedication to advancing neurovascular technology. With more than 25,000 patients treated with the WEB device worldwide, this intrasaccular device remains the trusted choice for physicians seeking a reliable, single-device solution for wide-neck bifurcation aneurysms.
About Terumo Neuro (Formerly MicroVention, Inc.)
We are in business to create and deliver Game-changing Impact™—innovations that redefine what is possible in neuroendovascular treatment to meaningfully advance both physician practice and patient outcomes. Founded in 1997 as MicroVention and acquired by Terumo Corporation in 2006, Terumo Neuro offers more than thirty products for the treatment of cerebral aneurysms, ischemic stroke, carotid artery disease, and neurovascular malformations. Headquartered in California, Terumo Neuro products are sold in more than seventy countries through a direct sales organization as well as strategic distribution partnerships. Manufacturing facilities are in Aliso Viejo, California, and San José, Costa Rica. For more information on Terumo Neuro, please visit www.terumoneuro.com.
About Terumo Corporation
Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for one hundred years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice. Terumo will further strive to be of value to patients, medical professionals, and society at large. For full indications for use, visit: WEBâ„¢ Embolization System | Terumo Neuro
*Information provided may not represent the approved indication for use for each country/market. Please refer to the Instruction for Use (IFU) in the specific market/country that you are looking into.
References:
WEBâ„¢ is a trademark of MicroVention, Inc., registered in the United States and other jurisdictions. All brand names are trademarks or registered trademarks owned by TERUMO CORPORATION, its affiliates, or unrelated third parties. ©2024 MicroVention, Inc. MM2034(i) WW 03/25
Media Contact:
Christine McCullough
Global Corporate Communications
Terumo Neuro
+ 1 714 206 9800
christine.mccullough@microvention.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Terumo Neuro Celebrates 15 Years of the WEB™ Device: A Game-Changing Innovation in Aneurysm Treatment
HANOI, Vietnam, Jan. 3, 2026 /PRNewswire/ -- Travellive Media Group is pleased to announce the HOTLIST Travellive Editor's Pick 2025 (HOTLIST 2025), a curated project honouring outstanding brands, destinations, and individuals that have made significant contributions to the development of Vietnam's tourism industry over the past year.
HOTLIST is a expert-curated list reflecting the evolving values of the market at each stage of development. The selection process combines the expertise of a prestigious advisory council comprising both domestic and international experts, based on key criteria including quality, innovation, social impact, and sustainable growth potential.
Last year, HOTLIST 2024 made a strong impression on the tourism, hospitality, and service community by recognising more than 40 brands and 12 inspiring individuals across 28 categories spanning hospitality and resorts, destinations, technology, and experiential initiatives. The year also marked the first time HOTLIST expanded into a professional event series, featuring The Insiders Forum and the Honor Ceremony, attracting over 700 guests including senior business leaders and experts from various fields.
HOTLIST 2025: From Seed to Harvest
Entering 2025, HOTLIST is developed under the theme "From Seed to Harvest" inspired by rice, a symbol deeply rooted in Vietnam's wet-rice civilisation and cultural identity. From planting ideas and nurturing resources to harvesting sustainable achievements, this metaphor reflects the authentic development journey of projects, brands, and destinations within the tourism and hospitality industry.
At a time when the tourism sector faces multiple challenges such as climate change, shifting traveller behaviour, and global competition, the spirit of "From Seed to Harvest" underscores the importance of long-term vision, perseverance, and adaptability.
This year, HOTLIST 2025 introduces a public voting component in the final evaluation stage, enabling the community and industry professionals to participate directly in the selection process. Beyond fostering engagement, this initiative also provides an opportunity for audiences to share their firsthand experiences with the shortlisted brands and projects.
HOTLIST 2025 Honourees
HOTLIST 2025 expands its scope across key tourism sectors, featuring 07 main categories: Hospitality; Aviation; Travel Design & Experiences; Destination; Technology & Innovations; Sustainability and Community Projects & Voices. Each category aims to identify exemplary individuals and brands that play a guiding role in shaping the future of Vietnam's tourism and hospitality industry.
This year's list continues to acknowledge well-established brands such as Four Seasons Resort The Nam Hai, Hoi An; Topas Ecolodge; Six Senses Ninh Van Bay; P'apiu Resort; Wink Hotels, among others. It also introduces international brands that have made a positive impact on the Vietnamese market, including voco Quang Binh Resort by IHG, Park Hyatt Phu Quoc, and Hyatt Place Halong Bay, Bai Chay. In the Aviation category, STARLUX AIRLINES was selected for its premium flight experience.
The expansion and diversification of award categories reflect HOTLIST's commitment to comprehensively capturing industry dynamics, while encouraging responsible development models that respect local identity and generate positive social impact.
As part of its mission to deliver practical value to the tourism industry, HOTLIST 2025 will host The Insiders Forum in Hanoi (7 January 2026, Sheraton Hanoi West) and Ho Chi Minh City (19 January 2026, JW Marriott Hotel & Suites Saigon). The forums will gather business leaders, experts, and researchers to share insights and discuss key topics shaping tourism landscape.
On 19 January 2026, The Honor Ceremony will take place in Ho Chi Minh City to officially recognise and present certificates to the brands, projects, and individuals featured in HOTLIST 2025. The event will also serve as a B2B networking platform for industry stakeholders.
Through each edition, HOTLIST Travellive Editor's Pick has gradually become a highly anticipated annual reference point for the tourism community, built on credibility, sustainability-driven orientation, and a series of professional programmes. Through recognition activities, dialogue forums, and community connections, Travellive not only highlights market excellence but also actively contributes to promoting sustainable thinking and elevating standards within tourism industry.
This year, HOTLIST 2025 is supported by The Brand Promise (Co-organiser of The Insiders Forum), PR Newswire (Media Partner), and sponsoring brands including BMWines, Lady Triệu (drink experiences), and Cocoon, Jourdeness (gifts). HOTLIST 2025 continues to amplify meaningful stories, connect outstanding individuals and organisations, and share positive values with the wider public.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
HOTLIST 2025 "From Seed to Harvest": A Story of Resilience and Transformation
